In medical circles, Sermorelin and Ipamorelin are often mentioned as a fountain of youth. While no single ingredient has the ability to reverse the aging process and stop our cells from deteriorating, this blend has shown promising results in a laboratory setting.

Both ingredients are human growth hormone-releasing peptides that stimulate the pituitary gland. Based on the studies conducted on animals, they are believed to preserve youthful anatomy and psychology.

What is Sermorelin?

Sermorelin is a synthetically made version of GHRH, or growth hormone-releasing hormone, which is responsible for promoting the natural release of growth hormone. It works by binding GHRH to the anterior part of the pituitary gland, stimulating the natural production of GH.

When doing research on rats and primates, scientists came up with the following benefits:

Sermorelin was able to:

• Increase muscles
• Increase lean body mass
• Decrease body fat
• Boost recovery from training sessions and injuries
• Enhance joint health and flexibility
• Improve overall wellness and health

What is Ipamorelin?

As the previous compound, Ipamorelin stimulates the release of growth hormone while reducing the release of somatostatin. Based on laboratory research, Ipamorelin has demonstrated the following benefits in the domain of anti-aging:

• Increased bone density
• Loss of body fat in obese adults
• Increased muscle mass
• Better immune system
• Improved cellular protein synthesis

Sermorelin and Ipamorelin Blend

These two peptides are often combined because they are believed to slow down aging processes, increase muscle mass, minimize inflammation, decrease fat mass, and health the gut. Research in pigs indicates that Sermorelin minimizes cell death of cardiomyocytes, boosts healing after cardiac injury, improves the collateral blood vessels, and reduces inflammation.

In addition to this, the administration of ghrelin analogues and ghrelin has been shown to lower abnormal heartbeats.

It has also been found that Sermorelin and Ipamorelin can benefit the central nervous system and boost sleep quality in animal models.

References:

Bagno LL, Kanashiro-Takeuchi RM, Suncion VY, Golpanian S, Karantalis V, Wolf A, Wang B, Premer C, Balkan W, Rodriguez J, Valdes D, Rosado M, Block NL, Goldstein P, Morales A, Cai RZ, Sha W, Schally AV, Hare JM. Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy. J Am Heart Assoc. 2015 Mar 31;4(4):e001464. doi: 10.1161/JAHA.114.001464. PMID: 25827134; PMCID: PMC4579962.

Kanashiro-Takeuchi RM, Szalontay L, Schally AV, Takeuchi LM, Popovics P, Jaszberenyi M, Vidaurre I, Zarandi M, Cai RZ, Block NL, Hare JM, Rick FG. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(12):9728-39. doi: 10.18632/oncotarget.3303. PMID: 25797248; PMCID: PMC4496393.

Tokudome T, Otani K, Miyazato M, Kangawa K. Ghrelin and the heart. Peptides. 2019 Jan;111:42-46. doi: 10.1016/j.peptides.2018.05.006. Epub 2018 May 20. PMID: 29791869.

Shepherd BS, Johnson JK, Silverstein JT, Parhar IS, Vijayan MM, McGuire A, Weber GM. Endocrine and orexigenic actions of growth hormone secretagogues in rainbow trout (Oncorhynchus mykiss). Comp Biochem Physiol A Mol Integr Physiol. 2007 Mar;146(3):390-9. doi: 10.1016/j.cbpa.2006.11.004. Epub 2006 Nov 24. PMID: 17240179.